Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients

BACKGROUND: Monoclonal antibodies (mAbs) targeting the spike of SARS-CoV-2 prevent severe COVID-19. Omicron subvariants BQ.1.1 and XBB.1.5 evade neutralization of therapeutic mAbs, leading to recommendations against their use. Yet, the antiviral activities of mAbs in treated patients remain ill-defi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruel, Timothée, Vrignaud, Lou-Léna, Porrot, Françoise, Staropoli, Isabelle, Planas, Delphine, Guivel-Benhassine, Florence, Puech, Julien, Prot, Matthieu, Munier, Sandie, Henry-Bolland, William, Soulié, Cathia, Zafilaza, Karen, Lusivika-Nzinga, Clovis, Meledge, Marie-Laure, Dorival, Céline, Molino, Diana, Péré, Hélène, Yordanov, Youri, Simon-Lorière, Etienne, Veyer, David, Carrat, Fabrice, Schwartz, Olivier, Marcelin, Anne-Geneviève, Martin-Blondel, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312842/
https://www.ncbi.nlm.nih.gov/pubmed/37398037
http://dx.doi.org/10.1101/2023.05.25.23290512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312842/
https://www.ncbi.nlm.nih.gov/pubmed/37398037
http://dx.doi.org/10.1101/2023.05.25.23290512

Ejemplares similares